Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Lifetime prevalence of 6-8% in the general population. Up to 20-30% in combat veterans and first responders. Approximately 12 million US adults have PTSD in a given year.
Trauma-focused CBT, EMDR, prolonged exposure therapy, CPT. SSRIs (sertraline, paroxetine) are first-line pharmacotherapy. Only ~50% of patients respond adequately, and many retain significant residual symptoms.
MDMA-assisted therapy (MAPS protocol) is the most advanced psychedelic treatment for PTSD. MDMA creates a state of reduced fear and enhanced trust that allows trauma processing without overwhelming anxiety. 3 medicine sessions over 12 weeks with intensive integration.
MAPP1 Phase 3: 67% no longer met PTSD criteria at primary endpoint. 71.2% response rate. Effect size d=0.91. MAPP2 confirmed efficacy across diverse populations. FDA Breakthrough Therapy designation.